Motor Neuron Disease (Mnd) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Motor Neuron Disease (MND) encompasses a group of progressive neurodegenerative disorders characterized by the selective degeneration of upper and/or lower motor neurons. Amyotrophic Lateral Sclerosis (ALS) is the most common form, but the spectrum includes progressive muscular atrophy, primary lateral sclerosis, and progressive bulbar palsy.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
- Amyotrophic Lateral Sclerosis (ALS): Combined upper and lower motor neuron involvement
- Progressive Muscular Atrophy (PMA): Lower motor neurons only
- Primary Lateral Sclerosis (PLS): Upper motor neurons only
- Progressive Bulbar Palsy (PBP): Brainstem motor nuclei involvement
- Loss of large motor neurons in anterior horn of spinal cord
- Bunina bodies: Small, eosinophilic inclusions
- ** ubiquitinated inclusions**: Skein-like inclusions
- TDP-43 pathology: Most ALS cases show TDP-43 aggregates
- Frontal cortex: Frontotemporal dementia in 15% of cases
- Basal ganglia: Involvement of striatal neurons
- Sensory neurons: Often spared
- Autonomic nervous system: Variable involvement
- C9orf72: Most common genetic cause (40% of familial ALS)
- SOD1: First discovered ALS gene
- FUS: RNA-binding protein pathology
- TARDBP: Encodes TDP-43
- Majority of cases without clear family history
- Complex environmental-genetic interaction
- Risk factors include smoking, trauma, toxins
- Muscle weakness (focal onset, then generalized)
- Muscle atrophy
- Fasciculations
- Spasticity (upper motor neuron signs)
- Dysarthria and dysphagia (bulbar involvement)
- Frontotemporal dysfunction in up to 50%
- Emotional lability
- Executive dysfunction
- Memory impairment (later stages)
- MRI: hyperintensity in corticospinal tract
- DTI: reduced fractional anisotropy
- PET: hypometabolism in frontal cortex
¶ CSF and Blood
- Elevated neurofilament light chain (NfL)
- Elevated phosphorylated neurofilament heavy chain (pNfH)
- Possible biomarkers for disease progression
- Riluzole: Glutamate antagonist, modest survival benefit
- Edaravone: Free radical scavenger, slows functional decline
- Muscle relaxants for spasticity
- Anticholinergics for drooling
- Feeding support and respiratory care
- Gene-targeted approaches (SOD1, C9orf72)
- Stem cell therapies
- Antisense oligonucleotides
- TDP-43 — key pathological protein
- C9orf72 — most common genetic cause
- ALS — most common MND form
The study of Motor Neuron Disease (Mnd) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Brown & Al-Chalabi, Amyotrophic lateral sclerosis (2017)
- Taylor et al., ALS genetics (2016)
- Hardiman et al., ALS pathophysiology (2017)
- Van Es et al., ALS clinical features (2017)